[go: up one dir, main page]

AR045752A1 - Derivados de quinazolina que poseen actividad antitumoral - Google Patents

Derivados de quinazolina que poseen actividad antitumoral

Info

Publication number
AR045752A1
AR045752A1 ARP040103319A ARP040103319A AR045752A1 AR 045752 A1 AR045752 A1 AR 045752A1 AR P040103319 A ARP040103319 A AR P040103319A AR P040103319 A ARP040103319 A AR P040103319A AR 045752 A1 AR045752 A1 AR 045752A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
group
alkoxy
alkylamino
Prior art date
Application number
ARP040103319A
Other languages
English (en)
Inventor
Robert Bradbury
Jason Kettle
Laurent Hennequin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045752(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR045752A1 publication Critical patent/AR045752A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente se refiere a derivados de quinazolina para su uso en la producción de un efecto antiproliferativo que es producido total o por la inhibición de la tirosina quinasa del receptor erbB2 en un animal de sangre caliente tal como el hombre. Reivindicación 1: un derivado de quinazolina caracterizado porque es de la fórmula (1) en donde: R1 se selecciona entre H, hidroxi alcoxi C1-6, cicloalquiloxi C3-7y cicloalquil C3-7-alcoxi C1-6 y en donde los átomos de C contiguos en cualquier cadena alquileno C2-6 dentro de un sustituyente R1 están opcionalmente separados por la inserción en la cadena de un grupo seleccionado entre O, S, SO, SO2, N(R), CO, CON(R3), N(R3)CO, SO2N(R3), y N(R3)SO2, en donde R3 es H o alquilo C1-6; y en donde cualquier grupo CH2 o CH3 dentro de un sustituyente R1 tiene opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes halógeno o alquilo C1-6, o un sustituyente seleccionado entre hidroxi, ciano, amino, carboxi, carbamoilo, sulfamoilo, oxo, tioxo, alcoxi C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[(C1-6)alquil]amino, alcoxicarbonilo C1-6, N-alquilcarbamoilo C1-6. N,N-di-[(C1-6)alquil]carbamoilo, alcanoilo C2-6, alcanoiloxi C2-6, alcanoilamino C2-6, N-alquil C1-6-alcanoilamino C2-6, N-alquilsulfamoilo C1-6, N,N-di[(C1-6)alquil]sulfamoilo, alcansulfonilamino C1-6 y N-alquil C1-6-alcansulfonilamino C1-6, Y se selecciona entre H, halógeno, alquilo C1-4, alcoxi C1-4, alquenilo C2-6 y alquinilo C2-4; a es 0, 1, 2, o 3 o 4; cada R2 que puede ser igual o diferente en cada caso, se selecciona entre halógeno, alquilo C1-4, alcoxi c1-4, alquenilo C2-4 y alquinilo C2-4, X2 es un enlace directo o se selecciona entre O, S, OC(R4)2, SC(R4)2, SO, SO2, N(R4), CO y N(R4)C(R4)2 en donde cada R4 que puede ser igual o diferente en cada caso, se selecciona entre H o alquilo C1-6, y Q2 es arilo o heteroarilo; y en donde Q2 tiene opcionalmente uno o más sustituyentes (por ejemplo 1, 2 o 3) que pueden ser iguales o diferentes, seleccionados entre halógeno, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, sulfamoilo, formilo, mercapto, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, alcoxi C1-6, alqueniloxi C2-6, alquiniloxi C2-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[(C1-6)alquil]amino, alcoxicarbonilo C1-6, N-alquilcarbamoilo C1-6, N,N-di-[(C1-6)alquil]carbamoilo, alcanoilo C2-6, alcanoiloxi C2- 6, alcanoilamino C2-6, N-alquil C1-6-alcanoilamino C2-6, alquenoilamino C3-6, N-alquil C1-6-alquenoilamino C3-6, alquinoilamino C3-6, N-alquil C1-6-alquinoilamino C3-6, N-alquilsulfamoilo C1-6, N,N-di-[(C1-6)alquil]sulfamoilo, alcansulfonilamino C1- 6, N-alquil C1-6-alcansulfonilamino C1-6, y u grupo de la fórmula -X4-R5 en donde X4 es un enlace directo o se selecciona entre O, CO y N(R6), en donde R6 es H o alquilo C1-6, y R5 es halógeno-alquilo C1-6, hidroxi-alquilo C1-6, carboxi-alquilo C1- 6, alcoxi C1-6-alquilo C1-6, ciano-alquilo C1-6, amino-alquilo c1-6, N-alquilamino C1-6-alquilo C1-6, N,N-di[(C1-6) alquil]amino-alquilo C1-6, alcanoilamino C2-6-alquilo C1-6, N-alquil C1-6-alcanoilamino C2-6-alquilo C1-6, alcoxicarbonilamino C1-6- alquilo C1-6, carbamoil-alquilo C1-6, N-alquilcarbamoil C1-6-alquilo C1-6, N,N-di-[(C1-6)alquil]carbamoil-alquilo C1-6, sulfamoil-alquilo C1-6, N-alquilsulfamoil C1-6-alquilo C1-6, N,N-di-alquilsulfamoil C1-6-alquilo C1-6, alcanoil C2-6-alquilo C1- 6, alcanoiloxi C2-6-alquilo C1-6 o alcoxicarbonil C1-6-alquilo C1-6, y en donde cualquier grupo CH2 o CH3 dentro de -X2-Q2 tiene opcionalmente en cada uno de dichos CH2 o CH3 uno o más (por ejemplo 1, 2, o 3) sustituyentes halógeno o alquilo C1-6 o un sustituyente seleccionado entre hidroxi, ciano, amino, alcoxi C1-4, alquilamino C1-4 y di-[(C1-4)alquil]amino; X1 es un enlace directo o C(R7)2 en donde cada R7, que puede ser igual o diferente en cada caso, se selecciona entre H y alquilo C1-4, el anillo Q1 es un grupo heterociclilo saturado o parcialmente insaturado de 4, 5, 6, o 7 miembros que contiene 1 heteroátomo de N y opcionalmente 1 o 2 heteroátomos adicionales seleccionados entre O, S y N, y cuyo anillo está unido al grupo X1 por un C del anillo, X3 es un grupo de la fórmula -(CR8R9)p-(Q3)m(CR10R11)q- en donde m es 0 o 1, p es 0, 1, 2, 3 o 4 y q es 0, 1, 2, 3 o 4, cada uno de R8, R9, R10 y R11, que puede ser igual o diferente en cada caso, se selecciona entre H y alquilo C1- 6, y Q3 se selecciona entre cicloalquileno C3-7 y cicloalquenileno C3-7; Z se selecciona entre hidroxi, amino, alquilamino C1-6, di[(C1-6)alquil]amino, alcoxi C1-6, alquilsulfonilo C1-6, alcansulfonilamino C1-6, N-alquil C1-6-alcansulfonilamino C1- 6, y un grupo de la fórmula Q4-X5- en donde X5 es un enlace directo o se selecciona entre O, N(R12), SO2 y SO2N(R12), en donde R12 es H o alquilo C1-6, y Q4 es cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, cicloalquenilo C3-7, cicloalquenil C3-7- alquilo C1-4, heterociclilo o heterociclil-alquilo C1-4, con la salvedad de que cuando X5 es un enlace directo, Q4 es heterociclilo, y con la salvedad de que cuando m, p y q son todos 0, entonces Z es heterociclilo, y en donde los átomos de C contiguos en cualquier cadena alquileno C2-6 dentro de un sustituyente Z están opcionalmente separados por la inserción en la cadena de un grupo seleccionado entre O, S, SO, SO2, N(R13), CO, -C=C- y -C=C- en donde R13 es H o alquilo C1-6, y en donde cualquier grupo CH2 o CH3 dentro de cualquier grupo Z, X1 o X3, a excepción de un grupo CH2 dentro de un anillo heterociclilo, tiene opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes halógeno o alquilo C1-6 o un sustituyente seleccionado entre hidroxi, ciano, amino, carboxi, carbamoilo, sulfamoilo, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[(C1-6)alquil]amino, N- alquilcarbamoilo C1-6, N,N-di-[(C1-6)alquil]carbamoilo, alcanoilo C2-6, alcanoiloxi C2-6, alcanoilamino C2-6, N-alquil C1-6-alcanoilamino C2-6, N-alquilsulfamoilo C1-6, N,N-di-[(C1-6)alquil]sulfamoilo, alcansulfonilamino C1-6 y N-alquil C1-6- alcansulfonilamino C1-6, y en donde cualquier grupo heterociclilo representado por Q1 o dentro de un sustituyente Z tiene opcionalmente uno o más (por ejemplo 1, 2 o 3) sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halógeno, trifluorometilo, ciano, nitro, hidroxi, amino, formilo, mercapto, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[(C1-6)alquil]amino, alcanoilo C2- 6, alcanoiloxi C2-6 y entre un grupo de la fórmula -X6-R14 en donde R6 es un enlace directo o se selecciona entre O, CO, SO2 y N(R15), en donde R15 es H o alquilo C1-4, y R14 es halógeno-alquilo C1-4, hidroxi-alquilo C1-4,alcoxi C1-4-alquilo C1-4, ciano-alquilo C1-4, amino-alquilo C1-4, N-alquilamino C1-4-alquilo c1-4 y N,N-di-[(C1-4)alquil]amino-alquilo c1-4, y en donde cualquier grupo heterociclilo representado por Q1 o dentro de un sustituyente Z opcionalmente tiene 1 o 2 sustituyentes oxo o tioxo, o una sal del mismo aceptable para uso farmacéutico.
ARP040103319A 2003-09-16 2004-09-16 Derivados de quinazolina que poseen actividad antitumoral AR045752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321648.8A GB0321648D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
AR045752A1 true AR045752A1 (es) 2005-11-09

Family

ID=29227164

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103319A AR045752A1 (es) 2003-09-16 2004-09-16 Derivados de quinazolina que poseen actividad antitumoral

Country Status (17)

Country Link
US (1) US20070015743A1 (es)
EP (1) EP1664029B1 (es)
JP (1) JP2007505874A (es)
CN (1) CN1882572A (es)
AR (1) AR045752A1 (es)
AT (1) ATE450528T1 (es)
AU (1) AU2004272351A1 (es)
BR (1) BRPI0414486A (es)
CA (1) CA2539024A1 (es)
DE (1) DE602004024420D1 (es)
GB (1) GB0321648D0 (es)
IL (1) IL174260A0 (es)
MX (1) MXPA06002965A (es)
NO (1) NO20061320L (es)
TW (1) TW200526628A (es)
WO (1) WO2005026152A1 (es)
ZA (1) ZA200602189B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423104T1 (de) * 2001-11-03 2009-03-15 Astrazeneca Ab Quinazolin derivate als antitumor-mittel
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
EP1664030A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
JP2007505871A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ キナゾリン誘導体
MXPA06002964A (es) * 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
BRPI0414447A (pt) * 2003-09-16 2006-11-14 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
CN1993349A (zh) * 2004-06-04 2007-07-04 阿斯利康(瑞典)有限公司 作为erbb受体酪氨酸激酶的喹唑啉衍生物
US7947676B2 (en) * 2004-12-14 2011-05-24 Astrazeneca Ab Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
NZ562109A (en) * 2005-06-16 2011-03-31 Myrexis Inc Pharmaceutical compositions containing substituted (4-Phenyl)-methyl-(quinazolin-4-yl)-amine compounds, uses thereof, and methods of preparing the same
WO2007034144A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
US20090239861A1 (en) * 2005-09-20 2009-09-24 Robert Hugh Bradbury Quinazoline derivatives as anticancer agents
CN101356171A (zh) 2005-11-15 2009-01-28 阿雷生物药品公司 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物
US20100222344A1 (en) * 2005-12-02 2010-09-02 Astrazeneca Ab 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
WO2007063293A1 (en) * 2005-12-02 2007-06-07 Astrazeneca Ab Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2008236994A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
EP2144888A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHODS OF TREATING CANCER
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
CN101939316B (zh) 2008-02-07 2013-10-02 贝林格尔.英格海姆国际有限公司 螺环杂环化合物、含有所述化合物的药物、其用途及其制备方法
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
RS56608B1 (sr) 2011-10-14 2018-02-28 Array Biopharma Inc Čvrsta disperzija
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT817613E (pt) * 1996-01-31 2005-06-30 Cosmoferm Bv Utilizacao de composicoes compreendendo enzimas estabilizadas
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6148197A (en) * 1998-03-06 2000-11-14 Sbc Technology Resources, Inc. Intelligent roaming system with over the air programming
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
KR20020068261A (ko) * 1999-02-27 2002-08-27 베링거 잉겔하임 파르마 카게 티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
ATE423104T1 (de) * 2001-11-03 2009-03-15 Astrazeneca Ab Quinazolin derivate als antitumor-mittel
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
UY28441A1 (es) * 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
JP2007505871A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ キナゾリン誘導体
BRPI0414447A (pt) * 2003-09-16 2006-11-14 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
MXPA06002964A (es) * 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
ES2281007T3 (es) * 2003-09-19 2007-09-16 Astrazeneca Ab Derivados de quinazolina.
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005030757A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1713781B1 (en) * 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
CN1993349A (zh) * 2004-06-04 2007-07-04 阿斯利康(瑞典)有限公司 作为erbb受体酪氨酸激酶的喹唑啉衍生物

Also Published As

Publication number Publication date
IL174260A0 (en) 2006-08-01
MXPA06002965A (es) 2006-06-14
EP1664029B1 (en) 2009-12-02
JP2007505874A (ja) 2007-03-15
AU2004272351A1 (en) 2005-03-24
GB0321648D0 (en) 2003-10-15
NO20061320L (no) 2006-04-26
EP1664029A1 (en) 2006-06-07
DE602004024420D1 (de) 2010-01-14
TW200526628A (en) 2005-08-16
ATE450528T1 (de) 2009-12-15
WO2005026152A1 (en) 2005-03-24
CA2539024A1 (en) 2005-03-24
CN1882572A (zh) 2006-12-20
US20070015743A1 (en) 2007-01-18
ZA200602189B (en) 2007-11-28
BRPI0414486A (pt) 2006-11-14

Similar Documents

Publication Publication Date Title
AR045752A1 (es) Derivados de quinazolina que poseen actividad antitumoral
CO5680435A2 (es) Derivados de quinazolina inhibidores de tirosina quinasa erbb y egb, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR047703A1 (es) Derivados de quinazolina
CY1124284T1 (el) Ενωσεις σπειρο[3η-ινδολο-3,2'-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53
AR039203A1 (es) Derivados de quinazolina
AR049294A1 (es) DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS.
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento
AR046308A1 (es) Derivados amida
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR045753A1 (es) Derivados de quinazolina, proceso de obtencion, uso y composiciones farmaceuticas.
AR035783A1 (es) Compuesto, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular efectos de los receptores de histamina 3
AR061873A1 (es) Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas.
AR045414A1 (es) Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
AR069078A1 (es) Derivados de piridina y pirazina
AR056197A1 (es) Derivados de 7-metilimidazol[1,2-a]piridin-6-il-8-metil-nonamidas como inhibidores de la renina, composciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de la hipertension arterial
AR044011A1 (es) Antagonistas de mchr1 heterociclicos
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
AR045754A1 (es) Derivados de quinazolina
AR047063A1 (es) Heterociclos azabiciclicos como moduladores de receptor canabinoide
AR054612A1 (es) Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes
AR051698A1 (es) Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
ES2093367T3 (es) Derivados de quinazolina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure